Latest NewsAug 22, 2024HiFiBiO Therapeutics to Present Phase 1 Clinical Trial Data for Two Novel Immuno-Oncology Antibodies at the 2024 Annual Congress of the European Society for Medical OncologyAll Filter By: Year2024202320222021202020192018201720162015Jul 3, 2020HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategyJun 22, 2020HiFiBiO Therapeutics Presents Three Novel Immuno-Oncology Programs at 2020 AACR Virtual Annual Meeting IIMay 15, 2020HiFiBiO Therapeutics Unveils Several Novel Antibodies Showing Promise to Be Precision Immunotherapies for Cancer PatientsMar 30, 2020Droplet Microfluidic Screening and Sequencing Can Vastly Expand the Universe of New Antibody TherapeuticsMar 30, 2020High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidicsJan 11, 2020Biotechs Build on Single-cell Analytics for Drug R&D, as Human Cell Atlas is Mapped< 1 … 8 9 10 11 12 … 14 >